Form 4 for TLX Telix Pharmaceuticals Ltd

Accepted 2026-05-06 21:32:08 ET · period of report 2026-04-28 · accession 0001628280-26-031608 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
MI	2026-05-06 21:32	2026-04-28+	TLX	Behrenbruch Christian	MD, Group CEO, Dir	P - Purchase	$14.67	+67.9K	20.74M	+0.3%	+$996.7K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Ordinary Shares	2026-04-28	P	A	34,500	$14.48	20,709,500	I Elk River Holdings Pty Ltd	—	—	(F1) The price reported in Column 4 is an average price. The shares were purchased in multiple transactions at prices ranging from $14.42 - $14.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission (SEC), upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (1) to this Form 4. (F2) The purchase prices are reported in Australian Dollars. (F3) Dr. Behrenbruch is the sole director and shareholder of Elk River Holdings Pty Ltd.
2	Common	Ordinary Shares	2026-04-29	P	A	33,435	$14.87	20,742,935	I Elk River Holdings Pty Ltd	—	—	(F2) The purchase prices are reported in Australian Dollars. (F4) The price reported in Column 4 is an average price. The shares were purchased in multiple transactions at prices ranging from $14.54 - $14.72, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the SEC, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in footnote (4) to this Form 4. (F3) Dr. Behrenbruch is the sole director and shareholder of Elk River Holdings Pty Ltd.